Gilead Sciences (GILD) PT Raised to $111 at Piper Jaffray Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) PT Lifted to $165 at BMO Capital on Strong Q2
July 24, 2014 6:40 AM EDTBMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following Q2 results.
Birchenough comments, "With SOVALDI continuing to set sales records on a background of incomplete insurance coverage in the U.S.,... More
Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
July 23, 2014 4:07 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $2.36, $0.63 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.53 billion versus the consensus estimate of $5.68 billion.
During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since Decembers launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical communitys recognition of the benefits of this product, said John C. Martin, PhD, Gileads Chairman and Chief Executive Officer. We look forward to making Sovaldi available in additional... More
